head JofIMAB
Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski Publishing Ltd.
ISSN: 1312-773X (Online)
Issue: 2022, vol. 28, issue1
Subject Area: Medicine
DOI: 10.5272/jimab.2022281.4223
Published online: 09 February 2022

Original article
J of IMAB. 2022 Jan-Mar;28(1):4223-4228
Koraliya Todorova-Nenova1ORCID logo Corresponding Autoremail, Maria Zhelyazkova-Savova2ORCID logo, Silvia Gancheva2ORCID logo, Elitsa Stoychev3ORCID logo,
1) Department of Psychiatry and Medical Psychology, Medical University - Varna, Bulgaria.
2) Department of Pharmacology and Clinical Pharmacology and Therapy, Faculty of Medicine, Medical University - Varna, Bulgaria.
3) Department of Pharmacology, Toxicology and Pharmacotherapy Faculty of Pharmacy, Medical University - Varna, Bulgaria.

Purpose: The present study aimed to evaluate the frequency of pDDIs in male patients admitted to a university-based intensive psychiatric unit over a twelve-month period and to assess patients' exposure to pDDIs as inpatients and potential outpatients.
Material/Methods: Charts of 425 consecutive hospitalized patients with psychiatric disorders were reviewed. Potential DDIs were assessed and categorized using Lexicomp® drug interaction software. Statistical analyses were performed with IBM SPSS Statistics for Windows, Version 20.0.
Results: A total of 1404 pDDIs (3.3 per patient) were identified for the hospitalization period. Categorized in risk rating categories X and D, considered most relevant for the safety of the patients were 346 (24.64%) of them. Among the pharmacodynamic pDDIs, most frequent were pDDIs associated with central nervous system depression, followed by QT‐interval prolongation.
Hospital discharge prescriptions included 631 pDDIs (1.48 per patient). Out of them, 144 (22.82%) were identified in risk rating categories X and D. Among the pharmacodynamic pDDIs first in frequency were pDDIs related to QT-interval prolongation, followed by pDDIs associated with central nervous system depression.
Potential DDIs that could lead to serotonin syndrome or extrapyramidal side effects were relatively infrequent during hospitalization and at discharge. No pharmacokinetic pDDIs were categorized in groups X and D.
Conclusions: The study showed a  higher frequency of pDDIs during the hospitalization period compared to hospital discharge with no change of the nature of the potential risks for the safety of the patients. Caution is warranted to limit the exposure of the patients to pDDIs.

Keywords: potential drug-drug interactions, psychiatric patients, discharge prescriptions,

pdf - Download FULL TEXT /PDF 502 KB/
Please cite this article as: Todorova-Nenova K, Zhelyazkova-Savova M, Gancheva S, Stoychev E. Potential drug-drug interactions in psychiatric patients during hospitalization and at hospital discharge. J of IMAB. 2022 Jan-Mar;28(1):4223-4228. DOI: 10.5272/jimab.2022281.4223

Corresponding AutorCorrespondence to: Koraliya Todorova-Nenova, Department of Psychiatry and Medical Psychology, Medical University – Varna; 55, Marin Drinov St, 9002 Varna, Bulgaria; E-mail: koralia.todorova@yahoo.com

1. Flynn E. Drug-drug interactions. In: xPharm: The Comprehensive Pharmacology Reference. Editors: Enna SJ, Bylund DB. Elsevier. 2007. pp.1-3. [Crossref]
2. Kapadohos T, Angelopoulos E, Vasileiadis I, Nanas S, Kotanidou A, Karabinis A, et al. Determinants of prolonged intensive care unit stay in patients after cardiac surgery: A prospective observational study. J Thorac Dis. 2017 Jan;9(1):70-79. [PubMed]
3. Moura CS, Acurcio FA, Belo NO. Drug-drug interactions associated with length of stay and cost of hospitalization. J Pharm Pharm Sci. 2009; 12(3):266-72. [PubMed]
4. Patel PS, Rana DA, Suthar JV, Malhotra SD, Patel VJ. A study of potential adverse drug-drug interactions among prescribed drugs in medicine outpatient department of a tertiary care teaching hospital. J Basic Clin Pharm. 2014 Mar;5(2):44–8. [PubMed]
5. Lexicomp® Drug Interactions - UpToDate.
6. Lucca JM, Ramesh M, Ram D, Kishor M. Incidence and predictors of adverse drug reactions caused by drug-drug interactions in psychiatric patients: An empirical study. Trop J Med Res. 2016 Jan-Jun;19(1):29-35.
7. Sandson NB, Armstrong SC, Cozza KL. Med-Psych drug-drug interactions update: an overview of psychotropic drug-drug interactions. Psychosomatics. 2005 Sep-Oct;46(5):464-94. [PubMed]
8. Vasudev A, Harrison R. Prescribing safely in elderly psychiatric wards: survey of possible drug interactions. Psychiatric Bulletin. 2008 Nov;32(11):417-8. [Crossref]
9. Ismail M, Iqbal Z, Khattak MB, Javaid A, Khan MI, Khan TM, et al. Potential drug-drug interactions in psychiatric ward of a tertiary care hospital: prevalence, levels and association with risk factors. Trop J Pharm Res. 2012 Apr;11(2):289-95. [Crossref]
10. Ocaña-Zurita MC, Juárez-Rojop IE, Genis A, Tovilla-Zárate CA, González-Castro TB, Lilia López-Narváez M, et al. Potential drug-drug interaction in Mexican patients with schizophrenia. Int J Psychiatry Clin Pract. 2016 Nov;20(4):249-53. [PubMed]
11. Sengul MCB, Karadag F, Sengul C, Karakulah K, Kalkanci O, Herken H. Risk of psychotropic drug interactions in real world settings: A pilot study in patients with schizophrenia and schizoaffective disorder. Klinik Psikofarmakol Bülteni.2014; 24(3):235-247. [Crossref]
12. Bertoli R, Bissig M, Caronzolo D, Odorico M, Pons M, Bernasconi E. Assessment of potential drug-drug interactions at hospital discharge. Swiss Med Wkly. 2010 Jul 15;140:w13043. [PubMed]
13. Hammar T, Lidström B, Petersson G, Gustafson Y, Eiermann B. Potential drug-related problems detected by electronic expert support system: physicians' views on clinical relevance. Int J Clin Pharm. 2015 Oct;37(5):941-8. [PubMed]
14. Sancar M, Kaєik A, Okuyan B, Batuhan S, Izzettin FV. Determination of Potential Drug-Drug Interactions Using Various Software Programs in a Community Pharmacy Setting. Turk J Pharm Sci. 2019 Mar;16(1):14-19. [PubMed]
15. Gonzaga de Andrade Santos TN, Mendonça da Cruz Macieira G, Cardoso Sodré Alves BM, Onozato T, Cunha Cardoso G, Ferreira Nascimento MT, et al. Prevalence of clinically manifested drug interactions in hospitalized patients: A systematic review and meta-analysis. PLoS One. 2020 Jul 1;15(7):e0235353. [PubMed]
16. Murtaza G, Khan MY, Azhar S, Khan SA, Khan TM. Assessment of potential drug-drug interactions and its associated factors in the hospitalized cardiac patients. Saudi Pharm J. 2016 Mar;24(2):220-5. [PubMed]
17. Worthley LI. Clinical Toxicology: Part I. Diagnosis and Management of Common Drug Overdosage. Crit Care Resusc. 2002 Sep;4(3):192-215. [PubMed]
18. Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Dtsch Arztebl Int. 2011 Oct;108(41):687-93. [PubMed]
19. Chung AK, Chua SE. Effects on prolongation of Bazett's corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: A meta-analysis. J Psychopharmacol. 2011 May;25(5):646–66. [PubMed]
20. Girardin FR, Gex-Fabry M, Berney P, Shah D, Gaspoz JM, Dayer P. Drug-induced long QT in adult psychiatric inpatients: The 5-year cross-sectional ECG screening outcome in psychiatry study. Am J Psychiatry. 2013 Dec;170(12):1468-76. [PubMed]
21. Davies SJC, Eayrs S, Pratt P, Lennard MS. Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards. Br J Clin Pharmacol. 2004 Apr;57(4):464-72. [PubMed].

Received: 02 June 2021
Published online: 09 February 2022

back to Online Journal